{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:00:24Z","timestamp":1780660824499,"version":"3.54.1"},"reference-count":32,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Mucous membrane pemphigoid (MMP) following anti\u2010programmed cell death\u20101 (PD\u20101) therapy is rare but increasingly reported. Management of high\u2010 and low\u2010risk MMP in this setting and the potential oncologic trade\u2010offs remain poorly defined. We performed a narrative synthesis of all published cases of anti\u2010PD\u20101\u2010associated MMP, following MEDLINE, Embase, and PubMed Central searches from January 2014 to June 2025. Fifteen cases from thirteen reports met the inclusion criteria, with a median MMP latency period of 12.5 weeks. The oral mucosa was frequently involved and was the index site in 84.6% (11\/13). Ocular involvement was observed in only one patient and resolved with topical corticosteroids (TCS). Anti\u2010PD\u20101 therapy was successfully continued in three low\u2010risk cases with systemic steroid treatment. Overall, doxycycline plus TCS produced the best low\u2010risk response: 5\/10 low\u2010risk patients were treated with doxycycline plus TCS; all five achieved complete remission (CR) at least at one anatomic site (3\/5 CR at all sites, 2\/5 CR with partial response (PR) at different sites). High\u2010risk MMP required escalation with methotrexate, rituximab, and\/or intravenous immunoglobulin (IVIg). Of the patients, 86.7% (13\/15) experienced CR or PR of MMP, and a single recurrence was reported. Tumor control (CR or PR) was maintained in 72.7%, with one relapse following anti\u2010PD\u20101 therapy cessation. Anti\u2010PD\u20101\u2010associated MMP is typically oral\u2010predominant and, unlike classic MMP, has infrequent ocular involvement. Management and therapeutic responses differed by site of involvement. Discontinuation of anti\u2010PD\u20101 is not always required. When anti\u2010PD\u20101 therapy continuation is clinically prioritized, a systemic steroid\u2010based regimen can stabilize MMP and facilitate completion of immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijd.70314","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T08:50:11Z","timestamp":1771059011000},"page":"1376-1382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mucous Membrane Pemphigoid After Anti\u2010\n                    <scp>PD<\/scp>\n                    \u20101 Therapy: Risk\u2010Stratified Management and Treatment Outcomes"],"prefix":"10.1111","volume":"65","author":[{"given":"Serena","family":"Dienes","sequence":"first","affiliation":[{"name":"Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"},{"name":"Faculty of Medicine and Dentistry University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Esfandiari","sequence":"additional","affiliation":[{"name":"Department of Dermatology Wayne State University  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Daveluy","sequence":"additional","affiliation":[{"name":"Department of Dermatology Wayne State University  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.008"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15679"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cden.2013.07.003"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000280"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2021.05.012"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14109"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2022.4364"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16780"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvoice.2022.12.028"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jds.2024.10.024"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.08.030"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.24294\/ti.v7.i2.2779"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00268"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16036"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.03.021"},{"issue":"4","key":"e_1_2_9_18_1","first-page":"290","article-title":"A Case of Nivolumab\u2010Associated Mucous Membrane Pemphigoid Involved Oral Mucosa","volume":"70","author":"Hayashi I.","year":"2021","journal-title":"JSS"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.370"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000767"},{"issue":"3","key":"e_1_2_9_22_1","first-page":"727","article-title":"PD\u20101\/PD\u2010L1 Pathway: Current Researches in Cancer","volume":"10","author":"Han Y.","year":"2020","journal-title":"American Journal of Cancer Research"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00550"},{"issue":"2","key":"e_1_2_9_24_1","article-title":"Importance of the PD\u20101\/PD\u2010L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia","volume":"9","author":"Ries J.","year":"2021","journal-title":"Biomedicine"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1443"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239147"},{"key":"e_1_2_9_27_1","volume-title":"Dupilumab [Package Insert]","author":"Dupixent","year":"2025"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae403"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18220"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754251351854"},{"issue":"10","key":"e_1_2_9_31_1","first-page":"1113","article-title":"Successful Treatment of Brunsting\u2010Perry Cicatricial Pemphigoid With Dupilumab","volume":"20","author":"Raef H. S.","year":"2021","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.40162"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3003"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70314","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.70314","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:03:57Z","timestamp":1780657437000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.70314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/ijd.70314"],"URL":"https:\/\/doi.org\/10.1111\/ijd.70314","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"2025-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}